Skip to Content
MilliporeSigma
Search Within
Document Type

87-99-0

Applied Filters:
Keyword:'87-99-0'
Showing 1-30 of 320 results for "87-99-0" within Technical Documents
The Effective Use of Protein Kinase Inhibitors
98 101 72 35 108 99 100 21 63 26 S6K1 0 94 32 98 93 92 86 100 87 75 106 81 25 109 95 101 6 32 18 GSK-3β 107 92 90 13 38 105 83
The Effective Use of Protein Kinase Inhibitors
98 101 72 35 108 99 100 21 63 26 S6K1 0 94 32 98 93 92 86 100 87 75 106 81 25 109 95 101 6 32 18 GSK-3β 107 92 90 13 38 105 83
PureFlex™ FILM: Extractables Bioreactivity Safety Evaluation Approach
calculations • USP 87> and testing of un-aged and aged samples was conducted by an accredited laboratory for USP biological testing. • USP 87>: Elution Method
MILLIPLEX®MAP Human Myokine Panel is an optimized quantitative immunoassay that simultaneously measures 15 novel muscle-secreted factors
00 0 7, 00 0 8, 00 0 9, 00 0 0 50 ,0 00 10 0, 00 0 15 0, 00 0 20 0, 00 0 25 0, 00 0 30 0, 00 010 10 0 1, 00 0 10 ,0 00 10 0, 00 0 10 10 0 1, 00 0 10 ,0 00
Flow-Through Removal of mAb Aggregates with Eshmuno®CP-FT Resin
CEX bind/elute Eshmuno® CPX 80 87% 0.42% 0% 0.42% 3 15.8 3. AEX flow-through Eshmuno® Q 150 >99% 0.43% 0% 0.43% 1 3.1 2. CEX flow-through Eshmuno® CP-FT 1000 92% 0.55% 0% 0.55% 17 13.6 3. AEX
LABORATORY NOTEBOOK ISSUANCE PAGE
tg en iu m 10 .8 1 12 .0 11 14 .0 07 15 .9 99 18 .9 98 20 .1 80 4. 00 26 26 .9 82 28 .0 85 30 .9 74 32 .0 6 35 .4
LABORATORY NOTEBOOK ISSUANCE PAGE
tg en iu m 10 .8 1 12 .0 11 14 .0 07 15 .9 99 18 .9 98 20 .1 80 4. 00 26 26 .9 82 28 .0 85 30 .9 74 32 .0 6 35 .4
Poster: Purification with Millipore MultiScreen 384SEQ Plates on Beckman-Coulter’s Biomek FX for High Quality Direct Sequencing in High-Throughput Genomics
Average Phred 37 37 39 Average > Phred 30 Readlength 323 321 353 % Pass Rate* 87% 83% 94% # of Resequenced Plates** 7 8 0 *Pass rate = number of samples with Phred score > 30 and at least 100 bp of
LABORATORY NOTEBOOK ISSUANCE PAGE
tg en iu m 10 .8 1 12 .0 11 14 .0 07 15 .9 99 18 .9 98 20 .1 80 4. 00 26 26 .9 82 28 .0 85 30 .9 74 32 .0 6 35 .4
Neutralization Efficacy of ICR Contact Plates App Note
neutralization of active residues. 120 98 56 97 112 102 101 80 87 159 98 87 69 101 118 0 20 40 60 80 100 120
Eshmuno® Q Resin for Efficient AEX Chromatography
47 15.1 2. CEX flow-through Eshmuno® CP-FT 1000 92% 0.55% 0% 0.55% 17 13.6 3. AEX flow-through Eshmuno® Q 150 >99% 0.61% 0% 0.61% 3 8.7 mAb 02 HCP in supernatant
Neutralizing Efficiency of Lecithin and Polysorbate 80 in ICR Contact Plates and Swabs for Surface Monitoring
102 89 104 111 85 97 80 109 99 84 91 117 101 108 99 109 99 128 87 108 83 92 95 93 159 126 125 0
Monitoring low dose API blend uniformity with Parteck® M
69 75 81 87 93 99 Lab data Calibration Set: Calculated vs Lab Data 105 111 117 123 129 135 129 135 123 117 111 105 99 M od el p re di ct ed d at
MultiScreen Assay System for High Throughput Cell-based Transport
Ratio 10 day 21 day 10 day 21 day Digoxin 11.5 30.5 6.6 14.5 % LY rejection AP/BL 99 >99 98 >99 Optimized Plate Design Improves Dynamic
Application Note – N-Boc protection
96% 96%96% 99% Boc Boc Boc Boc Boc BocBoc N H CF3 N CF3 HO N 99% 96% HO O O N H N H Me OH 96% 98%
Protocol- EZMCP1-99KRM|EZMCP1-99K5PKRM|EZMCP1-99K10PKRM
79.4 87 125 137.8 90 Plasma 4 0 21.6 31.25 50.3 92 62.5 75.7 87 125 131.6 88 Plasma 5 0 15.9
User Guide - Amicon® Ultra-2 Centrifugal Filter Devices
71 203 10 15 60 33 37 57 22 90 61 34 20 215 10 39 51 24 85 21 99 32 63 30 106 19 25 80 20 101 18 89 17 115 40 70
User Guide-RAB1062
Serum 95 86-101 Plasma 87 79-95 Cell Culture Supernatants 87 78-95 Linearity Sample Type Serum Plasma Cell Culture Supernatants 1:2 Average % of Expected 87 87 96 Range (%) 79-95 79-94
Amicon® Ultra-2 Centrifugal Filter Devices Non IVD User guide
71 203 10 15 60 33 37 57 22 90 61 34 20 215 10 39 51 24 85 21 99 32 63 30 106 19 25 80 20 101 18 89 17 115 40 70
S(–)-Blebbistatin: Selective inhibitor ofnon-muscle myosin II
Scand. J. Immunol., 56, 66-75 (1995). 98, Yoshida, K., et al., Proc. Natl. Acad. Sci. USA, 99, 4580-4585 (2002). 99. Hong, M. et al., Circulation, 104, 1176-1180 (2001). 100. Nantel, F. et al., “Altered bronchodilation
Human MCP-1 ELISA
Plasma 1 0 23.0 31.25 51.0 90 62.5 69.9 75 125 128.2 84 Plasma 2 0 18.9
Scalability of Mobius®Single-Use Bioreactors
94 95 96 97 98 99 100 0 2 4 6 8 10 12 % V ia bi lit y V ia bl e C el l D en si ty
Periodic table A4
Unknown title S ta n d : 0 1 /2 0 1 7 W .2 8 0 7 1 8 The life science business of Merck
Product Information Sheet-04693116001
incubation with the protease Pancreas extract 0.015 7.8 87 99 0.03 6.5 88 96 Pronase 0.0015 7.8 88 99 0.003 7.0 90 95 Thermolysin 0.0008 7.8 99 100 Chymotrypsin 0.0015 7.8 97 97 Trypsin 0.0002 7.8 93
Product Information Sheet - A6144
.V. et al., Analytical Biochem., 120, 176 (1982). 7. Tornheim K. et al., Analytical Biochem., 103, 87 (1980). 8. Wilson, J.E. and Chin A., Analytical Biochem., 193, 16 (1991). 9. Solheim, L.P. and Fromm
Product Information Sheet - A5394
.V. et al., Analytical Biochem., 120, 176 (1982). 7. Tornheim K. et al., Analytical Biochem., 103, 87 (1980). 8. Wilson, J.E. and Chin A., Analytical Biochem., 193, 16 (1991). 9. Solheim, L.P. and Fromm
Data Sheet - S3065
- Datasheet SC 19220 Product Number S 3065 Storage Temperature RT Cas #: 19395-87-0 Synonyms: 8–Chloro–dibenz[b,f][1,4]oxazepine- 10(11H)–carboxylic acid 2–acetylhydrazide O
Protocol- EZHTNFA-150K
4.9 9.4 102 14.8 19.0 99 44.7 47.5 97 Serum 5 0 3.7 4.9 8.0 87 14.8 16.4 86 44.7 41.4 85 Average 95 S am pl e
User Guide - EZHTNFA
4.9 9.4 102 14.8 19.0 99 44.7 47.5 97 Serum 5 0 3.7 4.9 8.0 87 14.8 16.4 86 44.7 41.4 85 Average 95 S am pl e
Understanding the Effect of Discreet PEG Linkers on ADC Structure and Binding
FcRn KD (nM) Rel. KD (%) KD (nM) Rel. KD (%) KD (nM) Rel. KD (%) Reference 0 169 100 468 100 392 100 LC-SMCC 4.1 195 87 465 101 309 128 PEG4 4.1 211 80 500 94 299 132 PEG8 4.0 200
Page 1 of 11